ATE378333T1 - Als biomarker geeignete cumarine - Google Patents

Als biomarker geeignete cumarine

Info

Publication number
ATE378333T1
ATE378333T1 AT03743381T AT03743381T ATE378333T1 AT E378333 T1 ATE378333 T1 AT E378333T1 AT 03743381 T AT03743381 T AT 03743381T AT 03743381 T AT03743381 T AT 03743381T AT E378333 T1 ATE378333 T1 AT E378333T1
Authority
AT
Austria
Prior art keywords
cumarins
biomarkers
cumarins suitable
Prior art date
Application number
AT03743381T
Other languages
English (en)
Inventor
Yves Auberson
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9932424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE378333(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE378333T1 publication Critical patent/ATE378333T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03743381T 2002-03-06 2003-03-05 Als biomarker geeignete cumarine ATE378333T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0205281.9A GB0205281D0 (en) 2002-03-06 2002-03-06 Organic compounds

Publications (1)

Publication Number Publication Date
ATE378333T1 true ATE378333T1 (de) 2007-11-15

Family

ID=9932424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743381T ATE378333T1 (de) 2002-03-06 2003-03-05 Als biomarker geeignete cumarine

Country Status (24)

Country Link
US (1) US7569337B2 (de)
EP (1) EP1483262B1 (de)
JP (2) JP4247123B2 (de)
KR (1) KR20040095257A (de)
CN (1) CN1628114A (de)
AR (1) AR038723A1 (de)
AT (1) ATE378333T1 (de)
AU (1) AU2003210418A1 (de)
BR (1) BR0308211A (de)
CA (1) CA2472298A1 (de)
CO (1) CO5611123A2 (de)
DE (1) DE60317476T2 (de)
EC (1) ECSP045255A (de)
ES (1) ES2294304T3 (de)
GB (1) GB0205281D0 (de)
MX (1) MXPA04008570A (de)
NO (1) NO20044174L (de)
PE (1) PE20030890A1 (de)
PL (1) PL370916A1 (de)
PT (1) PT1483262E (de)
RU (1) RU2004129733A (de)
TW (1) TW200400049A (de)
WO (1) WO2003074519A1 (de)
ZA (1) ZA200405175B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds
JP2007504283A (ja) * 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
JP2007084526A (ja) * 2004-11-26 2007-04-05 Nagasaki Univ アミロイド関連疾患診断用組成物
EP1815872A4 (de) * 2004-11-26 2011-06-15 Univ Nagasaki Zusammensetzung für die diagnose von amyloid-assoziierter erkrankung
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
RU2008150377A (ru) * 2006-05-19 2010-06-27 Нихон Меди-Физикс Ко., Лтд. (Jp) Новое соединение, обладающее сродством к амилоиду
TW200811175A (en) * 2006-06-21 2008-03-01 Nihon Mediphysics Co Ltd Novel compound with affinity with amyloid
AU2007261985B2 (en) * 2006-06-21 2012-04-19 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
EP2119458B9 (de) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Verfahren zur herstellung eines abbildungsmittels zur strahlendiagnose
EP2213672A4 (de) * 2007-10-24 2012-05-02 Nihon Mediphysics Co Ltd Neue verbindung mit affinität zu amyloid
KR20100089858A (ko) * 2007-10-30 2010-08-12 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
KR20100101577A (ko) * 2007-10-30 2010-09-17 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
JP6193881B2 (ja) * 2011-12-30 2017-09-06 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
EP2804852A2 (de) 2012-01-20 2014-11-26 Regents Of The University Of Minnesota Therapeutische verbindungen
CA2862084C (en) * 2012-01-26 2021-05-11 Ptc Therapeutics, Inc. 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy
ES2697174T3 (es) 2012-02-10 2019-01-22 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
KR102099997B1 (ko) * 2012-03-01 2020-04-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
US9914722B2 (en) 2012-03-23 2018-03-13 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN104987328A (zh) * 2012-05-23 2015-10-21 复旦大学 7-氧、硫或氮杂取代香豆素及其衍生物和用途
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
KR20220100719A (ko) 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
CN109476674B (zh) 2016-12-22 2021-12-10 伊鲁米纳剑桥有限公司 香豆素化合物及其作为荧光标记物的用途
CN108061725B (zh) * 2017-02-16 2020-04-21 昆明医科大学 1,8-萘啶基荧光分子探针在氯胺酮娱乐性滥用神经机制研究及成瘾程度诊断中的应用
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
MY209343A (en) 2019-03-01 2025-07-03 Illumina Cambridge Ltd Exocyclic amine substituted coumarin compounds and uses as fluorescent labels
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
CN112300201B (zh) * 2020-12-07 2021-11-23 南京林业大学 一种三聚茚基香豆素-咔咯-卟啉四元体系星型化合物的合成及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH390250A (de) * 1958-06-19 1965-07-30 Geigy Ag J R Verfahren zur Herstellung von fluoreszierenden Farbstoffen
DE2030507C3 (de) * 1970-06-20 1975-05-22 Bayer Ag, 5090 Leverkusen Oxazolyl-cumarine, deren Herstellung und Verwendung
JPS5529110B2 (de) * 1972-12-25 1980-08-01
DE2410634A1 (de) * 1974-03-06 1975-09-18 Basf Ag 3-benzofurylcumarine
DE2411969A1 (de) * 1974-03-13 1975-09-25 Bayer Ag Farbstofflaser
DE2525986A1 (de) * 1975-06-11 1977-05-05 Bayer Ag Cumarinverbindungen
LU78311A1 (de) * 1977-10-13 1979-06-01 Ciba Geigy Ag Neue cumarinfarbstoffe,deren herstellung und verwendung
US4892922A (en) * 1987-11-30 1990-01-09 Eastman Kodak Company Polyester polymer containing the residue of a benzopyran colorant compound and shaped articles produced therefrom
JPH01169327A (ja) * 1987-12-25 1989-07-04 Mitsui Toatsu Chem Inc 紫外線検知用樹脂組成物
JP2999841B2 (ja) * 1991-04-03 2000-01-17 三井化学株式会社 発光スクリーン用樹脂組成物
EP0527433B1 (de) 1991-08-13 1997-01-08 Bayer Corporation Fluoreszierendes Etikett
JPH073179A (ja) * 1993-06-15 1995-01-06 Nippon Kayaku Co Ltd インクジェットプリント用インク組成物及びこれを用いる染色法
JP4028155B2 (ja) 2000-04-11 2007-12-26 日本カーバイド工業株式会社 蛍光性再帰反射シート
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20040095257A (ko) 2004-11-12
NO20044174L (no) 2004-09-30
US7569337B2 (en) 2009-08-04
JP4247123B2 (ja) 2009-04-02
BR0308211A (pt) 2004-12-21
DE60317476T2 (de) 2008-05-21
CA2472298A1 (en) 2003-09-12
PL370916A1 (en) 2005-06-13
MXPA04008570A (es) 2004-12-06
PE20030890A1 (es) 2003-12-05
ECSP045255A (es) 2004-09-28
GB0205281D0 (en) 2002-04-17
JP2005526749A (ja) 2005-09-08
AU2003210418A1 (en) 2003-09-16
CO5611123A2 (es) 2006-02-28
CN1628114A (zh) 2005-06-15
JP2009102322A (ja) 2009-05-14
TW200400049A (en) 2004-01-01
US20050169837A1 (en) 2005-08-04
DE60317476D1 (de) 2007-12-27
ES2294304T3 (es) 2008-04-01
RU2004129733A (ru) 2005-06-27
EP1483262B1 (de) 2007-11-14
WO2003074519A1 (en) 2003-09-12
ZA200405175B (en) 2005-06-21
PT1483262E (pt) 2008-02-11
EP1483262A1 (de) 2004-12-08
AR038723A1 (es) 2005-01-26

Similar Documents

Publication Publication Date Title
DE60317476D1 (de) Als biomarker geeignete cumarine
DE60316900D1 (de) Analysevorrichtung
EP1573044A4 (de) Serum-biomarker bei lungenkrebs
DE602004011584D1 (de) Automatischer Analysator
DE602004012187D1 (de) Automatischer Analysator
DE602004012915D1 (de) Automatisches Analysengerät
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
EP1953736A4 (de) Stereo-codierungseinrichtung und stereosignal-prädiktionsverfahren
FI20021024A7 (fi) Päällysrakenne näppäimistöä varten
DE60316095D1 (de) Automatische Analysevorrichtung
DE60309104D1 (de) Automatische Analysevorrichtung
EP1735620A4 (de) Lungenkrebs-biomarker
DE602005024565D1 (de) Spektrometer
FR2861457B1 (fr) Systeme de controle non destructif
EP1837775A4 (de) Umkonfigurierbarer signalprozessor
EP1682512A4 (de) Immunohistochemische verfahren
ZA200700628B (en) Photometric analysis
DE602005001283D1 (de) Beleuchteter Tastschalter
DE60307009D1 (de) Automatischer Analysator
EP1828115A4 (de) 2-methylen-19-nor-(20s)-1alpha-hydroxytrishomopregnacalciferol
NO20020780D0 (no) Bildeanalyse
DE602004001250D1 (de) Tastatur
DE602004023341D1 (de) Chronograph
EP1784499A4 (de) Biomarker für blasenkrebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1483262

Country of ref document: EP

REN Ceased due to non-payment of the annual fee